SAN DIEGO, Calif., March 19, 2015 /PRNewswire/ -- Sequenom
Laboratories, a wholly owned subsidiary of Sequenom, Inc. (NASDAQ:
SQNM), a life sciences company committed to enabling healthier
lives through the development of innovative products and services,
and Recombine Inc., a clinical genetic testing company dedicated to
helping patients and providers make informed healthcare decisions,
today announced the launch of the HerediT® UNIVERSAL
carrier screening test as a service to ordering physicians. The
launch of this test expands Sequenom Laboratories' reach into the
universal carrier screening market.
"Carrier screening remains an important part of genetic risk
assessment and is now being utilized by physicians for patients
planning families," said William
Welch, President and Chief Executive Officer of Sequenom,
Inc.
The HerediT UNIVERSAL test screens for more than 250 genetic
diseases by analyzing over 2,000 genetic mutations. Current options
are limited to single gene testing or tests that can identify
approximately 100 hereditary conditions. This new offering can be
performed preconception or at any time during pregnancy.
"Though individually rare, genetic disorders are collectively
common and are a significant cause of childhood mortality," said
James Grifo, M.D., Ph.D., Program
Director of New York University,
Fertility Center. "An expanded carrier screening test provides an
opportunity to look beyond a patient's family history or ethnic
predispositions to particular diseases, which is increasingly
valuable as the obstetrics and gynecology (OB/GYN) physician
community incorporates broader screening into its routine standard
of care."
"We are excited to collaborate with Sequenom Laboratories, the
market leader in noninvasive prenatal testing, to bring this
expanded carrier screening technology to the OB/GYN and
maternal fetal medicine space," said Alex
Bisignano, Chief Executive Officer of Recombine. "This
strategic alliance will help us reach more patients, and enable
them to use comprehensive genetic testing and counseling services
to make informed decisions in family planning."
About Sequenom
Sequenom, Inc. (NASDAQ: SQNM) is committed to enabling healthier
lives through the development of innovative products and
services. The Company serves patients and physicians by
providing early patient management information.
About Sequenom Laboratories
Sequenom Laboratories, a CAP-accredited and CLIA-certified
molecular diagnostics laboratory, has developed a broad range of
laboratory tests, with a focus principally on prenatal care.
Branded under the names HerediT®, MaterniT21®
PLUS, SensiGene® and VisibiliT™, these
molecular genetic laboratory-developed tests provide early patient
management information for obstetricians, geneticists, and maternal
fetal medicine specialists. Sequenom Laboratories is changing the
landscape in genetic diagnostics using proprietary cutting edge
technologies. To learn how Sequenom is interpreting the genome for
improving the lives of patients everywhere, visit www.sequenom.com
and follow @SequenomLabs.
About Recombine, Inc.
Recombine is a clinical genetic testing company dedicated to
helping patients and providers make informed decisions based on
comprehensive and clinically actionable genetic testing results and
in-depth genetic counseling. Recombine joins experts in genetics,
fertility, and computer science brought together with one goal in
mind: to improve health outcomes with personalized genomic testing.
CarrierMap is Recombine's expanded carrier screening platform for
over 250 genetic diseases designed for patients and gamete donors
of all ethnicities. To learn how Recombine is leveraging the
unprecedented power of advanced technologies, visit
www.recombine.com and follow @Recombine.
SEQUENOM®, Sequenom Laboratories™,
HerediT®, MaterniT21® PLUS,
SensiGene® and VisibiliT™, are trademarks of
Sequenom, Inc. All other trademarks and service marks are the
property of their respective owners.
Forward-Looking Statements
Statements contained in this press release regarding matters that
are not historical facts are "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of
1995, including statements regarding the development of innovative
products and services, the obstetrics and gynecology (OB/GYN)
physician community incorporating broader screening into its
routine standard of care and the ability to reach more patients and
enable them to use comprehensive genetic testing and counseling
services to make informed decisions in planning their
families. Because such statements are subject to risks and
uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. Risks
are described more fully in the Company's filings with
the Securities and Exchange Commission, including without
limitation the Company's most recent Annual Report on Form 10-K and
other documents subsequently filed with or furnished to
the Securities and Exchange Commission. All
forward-looking statements contained in this press release speak
only as of the date on which they were made. The Company
undertakes no obligation to update such statements to reflect
events that occur or circumstances that exist after the date on
which they were made.
Logo - http://photos.prnewswire.com/prnh/20040415/SQNMLOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/sequenom-laboratories-launches-the-heredit-universal-test-in-collaboration-with-recombine-300053405.html
SOURCE Sequenom Laboratories